Skip to Main Content

Paper Details

Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report.
JTO Clin Res Rep
5
2022
Durvalumab, NSCLC, advanced NSCLC, patients, stage III NSCLC

Datasets

Release 1.2